

BEAT-CORONA: Building evidence to advance treatments for COVID-19

Submission date 22/04/2020	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 15/07/2020	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 21/07/2020	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe.

In 2020, the virus has spread to many countries around the world and neither a vaccine against the virus or specific treatment for COVID-19 has yet been developed. As of March 2020, it is advised that people minimize travel and social contact, and regularly wash their hands to reduce the spread of the virus.

Groups who are at a higher risk from infection with the virus, and therefore of developing COVID-19, include people aged over 70 years, people who have long-term health conditions (such as asthma or diabetes), people who have a weakened immune system and people who are pregnant. People in these groups, and people who might come into contact with them, can reduce this risk by following the up-to-date advice to reduce the spread of the virus.

BEAT-CORONA is a research study that will look at what makes COVID-19 infection more likely or more severe in some individuals, so we can understand how the disease spreads, and its impact on patients and the NHS. It will also help to support studies testing treatments that may prevent or cure COVID-19. In particular, it is focused on vulnerable populations such as kidney patients, vasculitis patients and inflammatory bowel disease patients and healthcare workers who are uniquely exposed to COVID-19 through occupational activities undertaken in diagnosing and treating patients. This study will conduct real-time monitoring of the impact of the outbreak on these groups of people using a smartphone application or the study website. Information will be collected including demographics and clinical data. Findings from this study will help to understand how different people are affected by COVID-19.

Who can participate?

Persons at risk of COVID-19.

What does the study involve?

Participants will be asked to submit information using the study smartphone application at baseline and periodically for as long as the study continues. Notifications and questionnaires will be sent to participants via in-app push notifications.

What are the possible benefits and risks of participating?

The benefits are that they will be contributing to the fight against COVID19 by helping doctors and the NHS to understand how people are affected by COVID19. As this is an observational study there are no risks associated with participation.

Where is the study run from?

Addenbrookes Hospital (UK)

When is the study starting and how long is it expected to run for?

May 2020 to April 2025

Who is funding the study?

Cambridge Biomedical Research Centre (UK)

Who is the main contact?

Unfortunately, this study is not recruiting public volunteers at this time. This is because the research isn't ready for volunteers yet or the researchers are directly identifying volunteers in certain areas or hospitals. Please do not contact the research team as they will not be able to respond. For more information about COVID-19 research, visit the Be Part of Research homepage.

Contact information

Type(s)

Public

Contact name

Dr Kerrie Brusby

Contact details

Cambridge Clinical Trials Unit
Box 401
Cambridge University Hospitals NHS Foundation Trust
Addenbrooke's Hospital
Level 6
Coton House
Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 254472
add-tr.beat-corona@nhs.net

Type(s)

Scientific

Contact name

Dr Thomas F Hiemstra

ORCID ID

<http://orcid.org/0000-0002-2115-8689>

Contact details

Cambridge Clinical Trials Unit
Box 40
Addenbrookes Hospital
Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 336817
tfh24@cam.ac.uk

Additional identifiers**EudraCT/CTIS number**

2020-002016-48

IRAS number

282317

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CTU0306, IRAS 282317

Study information**Scientific Title**

Building Evidence to Advance Treatments - COmpRehensive COhort NATional COVID-19 Study (BEAT-CORONA)

Acronym

BEAT-CORONA

Study objectives

The rationale of the study is to understand the epidemiology of COVID-19 infection in vulnerable groups (patients with kidney disease, vasculitis and related auto-immune disorders, inflammatory bowel disease and in the healthcare workforce) and its effect on clinical outcomes and the healthcare service.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Prospective observational comprehensive cohort study

Primary study design

Observational

Secondary study design

Epidemiological study

Study setting(s)

Internet/virtual

Study type(s)

Screening

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

COVID-19 (SARS-CoV-2 infection)

Interventions

Participants will be asked to submit information using the study smartphone application at baseline and periodically for as long as the study continues. Notifications and questionnaires will be sent to participants via in-app push notifications. Baseline data collected will include: baseline demographic data, baseline clinical data (comorbidities, medication, COVID-19 status and symptoms), smoking history and work environment (HCW only). Weekly follow-up data will include COVID-19 status.

Intervention Type

Other

Primary outcome measure

COVID-19 status, weekly during pandemic, via smartphone questionnaire

Secondary outcome measures

1. Risk factors for COVID-19 infection, weekly during pandemic, via smartphone questionnaire
2. Prognostic factors for clinical outcomes after COVID-19 infection, weekly during pandemic, via smartphone questionnaire

Overall study start date

06/04/2020

Completion date

30/04/2025

Eligibility

Key inclusion criteria

At risk of COVID-19

Participant type(s)

Mixed

Age group

Adult

Sex

Both

Target number of participants

There is no limit on the number of participants for BEAT-CORONA

Key exclusion criteria

Unable to provide informed consent

Date of first enrolment

24/08/2020

Date of final enrolment

01/05/2024

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre**Addenbrookes Hospital**

Cambridge University Hospitals NHS Foundation Trust

Hills Road

Cambridge

United Kingdom

CB2 0QQ

Sponsor information**Organisation**

Cambridge University Hospitals NHS Foundation Trust

Sponsor details

Cambridge Clinical Trials Unit
Addenbrooke's Hospital
Level 6
Coton House
Hills Road
Cambridge
England
United Kingdom
CB2 0QQ
+44 (0)1223 348158
cctu@addenbrookes.nhs.uk

Sponsor type

Hospital/treatment centre

Website

<http://www.cuh.org.uk/>

ROR

<https://ror.org/04v54gj93>

Organisation

University of Cambridge

Sponsor details

Trinity Lane
Cambridge
England
United Kingdom
CB2 1TN
+44 (0)1223 337733
researchgovernance@medschl.cam.ac.uk

Sponsor type

University/education

Website

<http://www.cam.ac.uk/>

ROR

<https://ror.org/013meh722>

Funder(s)**Funder type**

University/education

Funder Name

Cambridge Biomedical Research Centre

Results and Publications

Publication and dissemination plan

All publications will be approved by the BEAT-CORONA steering group. Reporting of results will be through publication of manuscripts in peer-reviewed journals and oral or poster presentations at relevant National or International meetings. As COVID-19 represents an emerging challenge, interim analyses may be made available via pre-print repositories ahead of publication in peer-reviewed journals or meetings. Audit datasets will be disseminated to relevant organisations with the agreement of the BEAT-CORONA steering group. Important findings may be communicated through local or National media as approved by the BEAT-CORONA steering group and Sponsor Communications teams.

All publications will be approved by the BEAT-CORONA SG. Reporting of results will be through publication of manuscripts in peer-reviewed journals and oral or poster presentations at relevant National or International meetings.

As COVID-19 represents an emerging challenge, interim analyses may be made available via pre-print repositories ahead of publication in peer-reviewed journals or meetings.

Audit datasets will be disseminated to relevant organisations with the agreement of the BEAT-CORONA steering group.

Important findings may be communicated through local or National media as approved by the BEAT-CORONA steering group and Sponsor Communications teams.

Intention to publish date

01/05/2025

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

IPD sharing plan summary

Available on request